Pivotal phase III trial of two dose levels of DAB(389)IL-2 (ONTAK (TM)) for the treatment of cutaneous T-cell lymphoma (CTCL)
Publication
, Journal Article
Olsen, EA; Duvic, M; Martin, A
Published in: JOURNAL OF INVESTIGATIVE DERMATOLOGY
April 1, 1998
Duke Scholars
Published In
JOURNAL OF INVESTIGATIVE DERMATOLOGY
ISSN
0022-202X
Publication Date
April 1, 1998
Volume
110
Issue
4
Start / End Page
678 / 678
Publisher
BLACKWELL SCIENCE INC
Related Subject Headings
- Dermatology & Venereal Diseases
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Olsen, E. A., Duvic, M., & Martin, A. (1998). Pivotal phase III trial of two dose levels of DAB(389)IL-2 (ONTAK (TM)) for the treatment of cutaneous T-cell lymphoma (CTCL). JOURNAL OF INVESTIGATIVE DERMATOLOGY, 110(4), 678–678.
Olsen, E. A., M. Duvic, and A. Martin. “Pivotal phase III trial of two dose levels of DAB(389)IL-2 (ONTAK (TM)) for the treatment of cutaneous T-cell lymphoma (CTCL).” JOURNAL OF INVESTIGATIVE DERMATOLOGY 110, no. 4 (April 1, 1998): 678–678.
Olsen EA, Duvic M, Martin A. Pivotal phase III trial of two dose levels of DAB(389)IL-2 (ONTAK (TM)) for the treatment of cutaneous T-cell lymphoma (CTCL). JOURNAL OF INVESTIGATIVE DERMATOLOGY. 1998 Apr 1;110(4):678–678.
Olsen, E. A., et al. “Pivotal phase III trial of two dose levels of DAB(389)IL-2 (ONTAK (TM)) for the treatment of cutaneous T-cell lymphoma (CTCL).” JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 110, no. 4, BLACKWELL SCIENCE INC, Apr. 1998, pp. 678–678.
Olsen EA, Duvic M, Martin A. Pivotal phase III trial of two dose levels of DAB(389)IL-2 (ONTAK (TM)) for the treatment of cutaneous T-cell lymphoma (CTCL). JOURNAL OF INVESTIGATIVE DERMATOLOGY. BLACKWELL SCIENCE INC; 1998 Apr 1;110(4):678–678.
Published In
JOURNAL OF INVESTIGATIVE DERMATOLOGY
ISSN
0022-202X
Publication Date
April 1, 1998
Volume
110
Issue
4
Start / End Page
678 / 678
Publisher
BLACKWELL SCIENCE INC
Related Subject Headings
- Dermatology & Venereal Diseases
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences